Wait ...what ? Am I understanding this correctly ?
alterity now has to do a 1 year preclinical study prior to advancing discussions with FDA on endpoints for a p2 ?
has the MSA route ( chosen to speed things up ) now backfired as no way to measure efficacy of p2 trial due to lack of data available so alterity now has to first produce said data ?
please tell me I'm wrong
Ann: Meeting with US FDA provides development path for ATH434, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
0.001(6.67%) |
Mkt cap ! $147.3M | |||
| Open | High | Low | Value | Volume |
| 1.5¢ | 1.7¢ | 1.5¢ | $770.2K | 49.71M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 2038332 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.6¢ | 349000 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| ATH (ASX) Chart |